- Lobbying
- astrazeneca
Lobbying Arrangements Results for 'Astrazeneca'
Former Covered Federal Workers:
Other Lobbyists:
Issue | Client | Firm | Lobbyists | Start Date | Latest Filing Date |
---|---|---|---|---|---|
Details 340B Programs |
AstraZeneca
|
Hogan Lovells US LLP | |||
Details Drug importation: FDA foreign drug inspection program; Medicaid drug rebates; direct to consumer advertising of pharmaceuticals. |
AstraZeneca Pharmaceuticals, LP
|
STUNTZ DAVIS & STAFFIER, P.C. | |||
Details 340B Programs |
AstraZeneca
|
Hogan Lovells US LLP | |||
Details Australian government policy on intellectual property and its impact on the Australian healthcare system |
AstraZeneca Pty Limited
|
CapitalHill Advisory | |||
Details Pharmaceutical Manufacturing |
AstraZeneca Pharmaceuticals LP
Pharmaceutical Manufacturing |
Bryan Cave Strategies, LLC | |||
Details Pharmacy compounding of prescription drugs |
AstraZeneca Pharmaceuticals LP
Pharmaceutical Manufacturer |
Venable LLP | |||
Details Issues related to general health care coverage. Food and Drug Administration legislative and regulatory issues. Medicare and Medicaid reform issues intellectual property issues Issues related to co... |
AstraZeneca Pharmaceuticals LP
|
Ogilvy Government Relations | |||
Details HR 4899, FY 10 War Supplement- provisions relating to patent settlements General outreach to Hill offices to introduce the company's business incentives |
AstraZeneca Pharmaceuticals LP
|
Bryan Cave LLP | |||
Details Monitor the status of legislation and issues pertaining to health care. |
AstraZeneca Pharmaceuticals LP
Pharmaceuticals. |
Bingham McCutchen LLP | |||
Details Development of policies to advance the antimicrobial research and development environment. Support of H.R.512 - DISARM Act of 2015 language in - H.R.6 - 21st Century Cures Act. |
AstraZeneca
|
The McManus Group, DBA Antimicrobial Innovation Alliance | |||
Details HR 2055 - Provisions relating to health and human services funding, Center for Disease Control and Prevention, burden of disease study on repiratory syncytial virus |
MedImmune LLC
|
SIDLEY AUSTIN LLP | |||
Details S 3712, A bill to make a technical correction in the Paul Wellstone and Pete Domenici Mental Health Parity and Addiction Equity Act of 2008. |
ASTRAZENECA PHARMACEUTICALS LP
|
Bryan Cave Strategies LLC | |||
Details Implementation of H.R.5376 - Inflation Reduction Act of 2022 and potential reforms involving the treatment of orphan drugs. H.R.2407 - Nancy Gardner Sewell Medicare Multi-Cancer Early Detection Sc... |
AstraZeneca Pharmaceuticals LP
|
W Strategies, LLC | |||
Details Issues related to access to pharmaceuticals. Patent Issues. Patent Reform. S. 1720: Patent Transparency and Improvements Act. H.R. 9: Innovation Act. |
AstraZeneca Pharmaceuticals LP
|
Thorsen French Advocacy LLC | |||
Details General health care coverage and reimbursement for prescription drugs; the Patient Protection and Affordable Care Act; and the Food and Drug Administration legislative and regulatory issues. |
AstraZeneca
|
East End Group, LLC | |||
Details Congressional deficit reduction negotiations and Deficit Reduction Commission, following passage of the Budget Control Act of 2011 (P.L. 112-25) |
ASTRAZENECA PHARMACEUTICALS LP
|
FOLEY HOAG LLP | |||
Details Issues relating to the effective implementation of PL 111-148 "The Patient Protection and Affordable Care Act," all provisions relating to mental health, and the ensuing budget reconciliation legis... |
ASTRAZENECA
|
GUIDE CONSULTING SERVICES, INC. | |||
Details Provide legislative and regulatory advice related to vaccine development, drug pricing, the 340B Drug Pricing Program, PDUFA Reauthorization, and clinical trial diversity; H.R.6000, Cures 2.0 Act; ... |
AstraZeneca Pharmaceuticals LP
|
Rampy Northrup LLC | |||
Details General Representation |
AstraZeneca Pharmaceuticals, LP
Pharmaceutical Company |
MEHLMAN VOGEL CASTAGNETTI, INC. | |||
Details HR 4679 - Stop Corporate Inversions Act of 2014, S. 2360 - Stop Corporate Inversions Act of 2014 (in the context of corporate acquisition activity). |
AstraZeneca Pharmaceuticals, LP
AstraZeneca is a global, innovation-driven, integrated biopharmaceutical company. |
Capitol Counsel LLC | |||
Details Advising on issues related to healthcare and sustainability |
AstraZeneca Pharmaceuticals LP
|
PRIME POLICY GROUP | |||
Details Drug Pricing. General issues related to rare disease and orphan drugs. General issues related to diagnostics for patients with rare diseases. Items related to the Administrations Cancer Moonshot. P... |
AstraZeneca Pharmaceuticals LP
|
Todd Strategy Group | |||
Details Medicare Part B and FDA. Cancer Payment Reform Legislation S. 462. Issues related to the 340B Drug discount program.Issues related to the part D donut hole. Medicare Part B and FDA. Cancer Payment ... |
AstraZeneca Pharmaceuticals LP
|
Farragut Partners LLP | |||
Details Seeking consideration of AstraZeneca's intention to substitute zero Global Warming Potential (GWP) gases for current propellants in its metered dose inhalers. |
AstraZeneca UK Ltd.
|
Squire Patton Boggs | |||
Details HR 4679 Stop Corporate Inversions Act of 2014, S 2360 Stop Corporate Inversions Act of 2014 (in the context of corporate acquisition activity) |
AstraZeneca Pharmaceuticals LP
|
The Glover Park Group LLC | |||
Details Medicare prescription drug benefit; Drug rebates for Medicare Part D; Part D benefit structure; Payment policies for Medicare Part B Prescription drugs; Independent Payment Advisory Board (IPAB), r... |
AstraZeneca Pharmaceuticals LP (formerly AstraZeneca Pharmaceuticals Group)
|
Williams and Jensen, PLLC | |||
Details COVID-19 vaccine development, manufacturing, and distribution |
Burson Cohn & Wolfe on behalf of AstraZeneca Pharmaceuticals LP
Biopharmaceutical company |
Prime Policy Group | |||
Details Pharmaceutical distribution and supply chain security. |
Pharmaceutical Distribution Security Alliance (PDSA)
|
Leavitt Partners, LLC | |||
Details Issues related to implementation of drug pricing and reimbursement of prescription drugs provision in The Inflation Reduction Act of 2022 (PL 117-169); Issues relating to Medicare Part D and Part B... |
AstraZeneca
|
Tiber Creek Group | |||
Details Federal budget issues Medicare and Medicaid drug coverage and reimbursement IRA implementation, 340B, orphan drug issues, oncology, transparency |
AstraZeneca
|
TARPLIN, DOWNS & YOUNG, LLC | |||
Details International trade issues, including free-trade agreements, import safety. H.R. 2182, Generating Antibiotic Incentives Now (GAIN) Act. Prescription Drug User Fee Act (PDUFA) Budget Control A... |
ASTRAZENECA PHARMACEUTICALS
|
MEHLMAN VOGEL CASTAGNETTI, INC. | |||
Details Issues relating to access and coverage of immunizations, including vaccine safety net for uninsured adults, and recovery of missed routine adult vaccines. H.R.4420 - Preparedness and Response Reaut... |
Adult Vaccine Access Coalition
|
NVG, LLC | |||
Details FDA modernization policy issues Reauthorization of newborn screening programs General issues related to rare disease and orphan drugs General issues related to health equity in rare disease and ... |
AstraZeneca Pharmaceuticals LP
|
in-house lobbying |